HKPMDC
 All     Test   
 
Infectious Disease
Infectious Disease


Test Name: HBV Drug Resistant Mutation Detection
Compliance:LDT
Test Description:Treatment of chronic hepatitis B (CHB) is geared to achieving sustained suppression of hepatitis B virus (HBV) replication and remission of liver disease, with the aim of preventing liver failure, cirrhosis, and hepatocellular carcinoma. Several drugs have been approved for treatment, including interferon-alfa, peginterferon alfa-2, and the nucleotide/nucleoside analogs (NAs) lamivudine (3TC), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (LdT), and tenofovir (TDF). Mutations in the HBV genome, and the HBV genotype itself, may affect treatment response and disease course. Treatment with NAs can lead to prolonged viral suppression (loss of HBV DNA, antigen seroconversion, and, rarely, HBsAg loss and HBsAb appearance) in patients with HBV infection. However, prolonged therapy may select for mutations in the HBV DNA polymerase gene (including M204V in the YMDD motif), leading to drug resistance. The rate of acquired resistance varies with the NA used and baseline viral load, among other factors.
Methodology:PCR-Sanger sequencing of HBV polymerase gene
Gene Name:

HBV

Protein Name:
Specimen Requirements:EDTA Blood (5mL)
Storage Condition:Ambient Temperature / 4℃ (if overnight is needed)
Turn Around Time:5 working days from day of specimen received
OMIM:
Genetic Home Reference:
Phone: +852.2986.1213
Fax:+852.2527.7028
E-mail:contact@hk-mpdc.com
35/F, Enterprise Square Two, 3 Sheung Yuet Road, Kowloon Bay, Hong Kong
Opening Hours
Mondays to Fridays: 09:00-18:00
Saturdays: 09:00-16:00
Sundays and Public Holidays: Closed

For specimen pickup arrangements, please phone +852.2986.1213


Shipping & Billing Information

HOKLAS accreditation scope